News

TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed

TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed

A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
WHO Maintains Official Relations With TIF For 2021-2024

WHO Maintains Official Relations With TIF For 2021-2024

We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for 2021-2024 The extension of ΤIF’s official relations with WHO was…
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
Iranian Blood Transfusion Organization Newsletter – December 2020

Iranian Blood Transfusion Organization Newsletter – December 2020

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…
Back to top button